| Schedule of Disaggregation of Revenue |
The table below provides a disaggregation of revenues by type and customer location for the three and six months ended June 30, 2026 and 2025:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | (in thousands) | | 2026 | | 2025 | | 2026 | | 2025 | | Types of goods and services | | | | | | | | | | Product revenues, net | | $ | 18,634 | | | $ | 18,085 | | | $ | 38,667 | | | $ | 35,489 | | | License revenues | | — | | | — | | | — | | | 5,000 | | | | | | | | | | | | Royalties | | 614 | | | 754 | | | 1,432 | | | 1,383 | | | Total revenue | | $ | 19,248 | | | $ | 18,839 | | | $ | 40,099 | | | $ | 41,872 | | | | | | | | | | | | Customer Location | | | | | | | | | | U.S. | | $ | 18,634 | | | $ | 18,085 | | | $ | 38,667 | | | $ | 35,489 | | EMEA(1) | | 614 | | | 754 | | | 1,432 | | | 6,383 | | | | | | | | | | | | Total revenue | | $ | 19,248 | | | $ | 18,839 | | | $ | 40,099 | | | $ | 41,872 | |
(1) Europe, the Middle East and Africa The table below provides a rollforward of the Company’s accruals related to the gross-to-net (“GTN”) sales adjustments for the three and six months ended June 30, 2026:
| | | | | | | | | | | | | | | | | | | | | | (in thousands) | | Discarded Drug Rebate | | Other Adjustments | | Total | | Balance as of March 31, 2026 | | $ | 10,175 | | | $ | 2,374 | | | $ | 12,549 | | | GTN accruals for current period | | 2,058 | | | 4,503 | | | 6,561 | | | Prior period adjustments | | — | | | (258) | | | (258) | | | Credits, payments and reclassifications | | — | | | (4,525) | | | (4,525) | | | Balance as of June 30, 2026 | | $ | 12,233 | | | $ | 2,094 | | | $ | 14,327 | | | | | | | | | | Balance as of December 31, 2025 | | $ | 7,964 | | | $ | 2,714 | | | $ | 10,678 | | | GTN accruals for current period | | 4,269 | | | 9,485 | | | 13,754 | | | Prior period adjustments | | — | | | (679) | | | (679) | | | Credits, payments and reclassifications | | — | | | (9,426) | | | (9,426) | | | Balance as of June 30, 2026 | | $ | 12,233 | | | $ | 2,094 | | | $ | 14,327 | |
The table below provides a rollforward of the Company’s accruals related to the gross-to-net (“GTN”) sales adjustments for the three and six months ended June 30, 2025:
| | | | | | | | | | | | | | | | | | | | | | (in thousands) | | Discarded Drug Rebate | | Other Adjustments | | Total | | Balance as of March 31, 2025 | | $ | 9,672 | | | $ | 2,367 | | | $ | 12,039 | | | GTN accruals for current period | | 2,020 | | | 3,904 | | | 5,924 | | | Prior period adjustments | | — | | | (241) | | | (241) | | | Credits, payments and reclassifications | | — | | | (3,540) | | | (3,540) | | | Balance as of June 30, 2025 | | $ | 11,692 | | | $ | 2,490 | | | $ | 14,182 | | | | | | | | | | Balance as of December 31, 2024 | | $ | 15,103 | | | $ | 2,386 | | | $ | 17,489 | | | GTN accruals for current period | | 3,969 | | | 8,010 | | | 11,979 | | | Prior period adjustments | | (200) | | | (573) | | | (773) | | | Credits, payments and reclassifications | | (7,180) | | | (7,333) | | | (14,513) | | | Balance as of June 30, 2025 | | $ | 11,692 | | | $ | 2,490 | | | $ | 14,182 | |
The table below provides the classification of the accruals related to the GTN sales adjustment included in the Company’s unaudited condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025.
| | | | | | | | | | | | | | | | (in thousands) | | June 30, 2026 | | December 31, 2025 | | Accounts receivable, net | | $ | 1,607 | | | $ | 1,658 | | | Other current and non-current liabilities | | 12,720 | | | 9,020 | | | | $ | 14,327 | | | $ | 10,678 | |
|